What are the recommendations for the shingles vaccine in adults aged 50 and older, including those with a history of shingles or weakened immune systems?

Shingles Vaccine Recommendations

Primary Recommendation

All adults aged 50 years and older should receive Shingrix (recombinant zoster vaccine) as a 2-dose series, with the second dose given 2-6 months after the first, regardless of prior shingles history or previous Zostavax vaccination. 1, 2

---

Standard Vaccination Schedule

Immunocompetent Adults ≥50 Years

• First dose: Administer immediately upon reaching age 50 2
• Second dose: Give 2-6 months after the first dose 1, 2
• Minimum interval: 4 weeks between doses (if given earlier, repeat the dose) 1
• Route: Intramuscular injection 1

Immunocompromised Adults ≥18 Years

• Accelerated schedule: Second dose at 1-2 months after the first dose 1, 2
• This includes patients with:
  • HIV infection 2
  • Cancer (solid tumors or hematologic malignancies) 1
  • Autoimmune diseases requiring immunosuppressive therapy 1, 2
  • Solid organ or stem cell transplant recipients 1, 2
  • Patients on biologics, JAK inhibitors, or other immunomodulators 1

---

Efficacy and Protection

Shingrix demonstrates 97.2% efficacy in preventing shingles in adults aged 50 and older, with protection sustained above 83.3% for at least 8 years. 1 This represents dramatically superior performance compared to the older Zostavax vaccine, which declined to only 14.1% efficacy by year 10. 1, 2

The vaccine maintains high efficacy across all age groups, unlike Zostavax which showed 70% efficacy in ages 50-59 but only 18% in those ≥80 years. 1

---

Special Clinical Scenarios

After a Shingles Episode

• Wait at least 2 months after acute symptoms resolve before vaccinating 1, 2
• Prior shingles does NOT eliminate the need for vaccination—the 10-year recurrence risk is 10.3% 1
• Having shingles once does not provide reliable protection against future episodes 1

Previous Zostavax Recipients

• Give the full 2-dose Shingrix series at least 2 months after the last Zostavax dose 1, 2
• No maximum interval exists—patients who received Zostavax years ago should still receive Shingrix 1
• Zostavax provides inadequate long-term protection and must be replaced with Shingrix 1, 2

Patients on Immunosuppressive Therapy

• Complete the 2-dose series BEFORE starting immunosuppressive medications whenever possible 1
• For urgent medication initiation (e.g., tofacitinib for severe disease):
  • Give first Shingrix dose immediately
  • Start medication 2-3 weeks after first vaccine dose
  • Complete second Shingrix dose 1-2 months later 1
• Never use live Zostavax in immunocompromised patients—only Shingrix is safe 1, 2

Patients on Glucocorticoids

• Shingrix can be safely administered to patients taking any dose of glucocorticoids 1
• Low-dose prednisone (<10 mg/day equivalent) does not adversely impact vaccine response 1
• Studies show only mild disease flares (4-17%) with no serious adverse events 1

During Neutropenia or Chemotherapy

• Shingrix is NOT contraindicated during neutropenia (unlike live vaccines) 1
• Consider timing between chemotherapy cycles (>7 days after last treatment) when feasible to optimize response 1
• Live Zostavax is absolutely contraindicated in this population 1

---

Important Caveats and Pitfalls

Common Mistakes to Avoid

1. Do NOT delay vaccination in adults ≥50 years to check varicella serology—vaccination is recommended regardless of antibody status 1, 2
2. Do NOT use Zostavax for any patient who is or will become immunocompromised—only Shingrix is appropriate 1, 2
3. Do NOT assume one dose is sufficient—both doses are required for optimal protection 1
4. Do NOT wait for "ideal timing" in immunocompromised patients—vaccinate as soon as feasible, even if already on immunosuppression 1

No Booster Doses Needed

• No additional doses beyond the initial 2-dose series are currently recommended 1
• Protection remains robust for at least 8 years without waning requiring a booster 1

---

Expected Side Effects

Local Reactions (Very Common)

• Injection site pain, redness, swelling 1, 3
• Grade 3 injection site reactions occur in 9.5% (vs. 0.4% with placebo) 1

Systemic Symptoms (Common)

• Myalgia, fatigue, headache 1, 3
• Systemic symptoms in 11.4% (vs. 2.4% with placebo) 1
• Most resolve within 4 days 1, 2

Safety Profile

• No serious safety concerns identified in large clinical trials 1, 4
• Similar rates of serious adverse events between vaccine and placebo groups 1
• Post-licensure surveillance of 647,833 doses confirmed no sustained increased risk of stroke, anaphylaxis, or Guillain-Barré syndrome 4

---

Timing with Other Vaccines

Shingrix can be administered simultaneously or sequentially with inactivated influenza vaccines with no required waiting period. 1 Wait until acute flu symptoms (fever, severe malaise) have resolved before vaccinating, but no specific interval is required after illness resolution. 1

---

Why Shingrix Over Zostavax

The evidence overwhelmingly favors Shingrix:

• 97.2% vs. 51-70% initial efficacy 1, 5
• Sustained protection vs. rapid decline (83.3% at 8 years vs. 14.1% at 10 years) 1, 2
• Safe for immunocompromised patients (Zostavax is contraindicated) 1, 2
• Consistent efficacy across all ages (Zostavax drops to 18% in those ≥80 years) 1

Zostavax is no longer the preferred vaccine and should not be used for new vaccinations. 1, 2